Senescent Cells in Early Vascular Ageing and Bone Disease of Chronic Kidney Disease-A Novel Target for Treatment

Together with bone-mineral disorders, premature vascular ageing is a common feature of the uremic phenotype. A detailed understanding of mechanisms involved remains unclear and warrants further research. Available treatment options for end stage renal disease are principally dialysis and organ trans...

Full description

Saved in:
Bibliographic Details
Published inToxins Vol. 11; no. 2; p. 82
Main Authors Hobson, Sam, Arefin, Samsul, Kublickiene, Karolina, Shiels, Paul G, Stenvinkel, Peter
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 01.02.2019
MDPI
Subjects
Age
ageing
Aging
Aging - physiology
Animals
Apoptosis
Biomarkers
Bone diseases
Bone Diseases - drug therapy
Calcification
Cardiovascular pathology
Cellular Senescence
chronic kidney disease
Dialysis
Environmental factors
Genotype & phenotype
Humans
Kidney diseases
Kidney transplantation
Kidneys
Kinases
Lifestyles
Medicin och hälsovetenskap
Metabolism
Morbidity
Mortality
Nrf2
Oxidative stress
Phenotypes
Physiology
Renal Insufficiency, Chronic - drug therapy
Review
Senescence
Transplantation
uremic toxins
Vascular Calcification - drug therapy
senescence
ageing
chronic kidney disease
uremic toxins
Nrf2
Online AccessGet full text

Cover

More Information
Summary:Together with bone-mineral disorders, premature vascular ageing is a common feature of the uremic phenotype. A detailed understanding of mechanisms involved remains unclear and warrants further research. Available treatment options for end stage renal disease are principally dialysis and organ transplantation, as other treatment alternatives have proven insufficient. Chronic kidney disease (CKD) has been proposed as a model of early vascular and bone ageing, with accumulating evidence supporting the contribution of cellular senescence and the senescence-associated secretory phenotype (SASP) to cardiovascular pathology in CKD. Correspondingly, novel therapies based around the use of senolytic compounds and nuclear factor-erythroid-2-related factor 2 (Nrf2) agonists, have been suggested as attractive novel treatment options. In this review, we detail the contribution of the uremic environment to these processes underpinning ageing and how these relate to vascular health.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2072-6651
2072-6651
DOI:10.3390/toxins11020082